Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience

BACKGROUND: The US Food and Drug Administration issued an Emergency Use Authorization for remdesivir use in patients with severe COVID-19. METHODS: We utilized data from 2 quaternary acute care hospitals. The outcomes of interest were the impact of remdesivir on in-hospital death by day 28 and time...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalligeros, Markos, Tashima, Karen T, Mylona, Evangelia K, Rybak, Natasha, Flanigan, Timothy P, Farmakiotis, Dimitrios, Beckwith, Curt G, Sanchez, Martha, Neill, Marguerite, Johnson, Jennie E, Garland, Joseph M, Aung, Su, Byrd, Katrina M, O’Brien, Thomas, Pandita, Aakriti, Aridi, Jad, Macias Gil, Raul, Larkin, Jerome, Shehadeh, Fadi, Mylonakis, Eleftherios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454852/
https://www.ncbi.nlm.nih.gov/pubmed/33117850
http://dx.doi.org/10.1093/ofid/ofaa319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454852/
https://www.ncbi.nlm.nih.gov/pubmed/33117850
http://dx.doi.org/10.1093/ofid/ofaa319

Ejemplares similares